Auris Medical Completes Acquisition of AM-125 Assets
(WorldNews Switzerland)

Closing of asset transfer from Otifex Therapeutics Rights to additional preclinical and clinical data complement scope of data package Initiation of Phase 1 trial of AM-125 planned for the fourth quarter of 2017 ZUG, Switzerland, July 20, 2017 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important, unmet medical needs in otolaryngology, today announced that it has completed its acquisition of various assets related to intranasal betahistine from Otifex Therapeutics Ltd. The assets, which comprise preclinical and clinical data as well as intellectual property rights, have been fully transferred to Auris...